

LIST OF MATERIALS CONSIDERED

Description	Exhibit
U.S. Patent No. 10,323,092 B2	1001
U.S. Patent 7,595,048 (“Honjo-Freeman ’048”)	1009
U.S. Application No. 16/006,473	1010
U.S. Provisional Application No. 61/647,442	1011
U.S. Provisional Application No. 61/790,747	1012
Okazaki and Honjo, <i>PD-1 and PD-L1 ligands: from discovery to clinical application</i> , 19(7) Int. Immunol. 813 (2007)	1013
Iwai et al., <i>Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade</i> , 99(19) Proc. Nat. Acad. Sci. 12293 (2002)	1014
Blank et al., <i>Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy</i> , 54 Cancer Immunol. Immunother. 307 (2005)	1015
Iwai et al., <i>PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells</i> , 17(2) Int. Immunol. 133 (2004)	1016
Brown et al., <i>Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production</i> , 170 J. Immunol. 1257 (2003)	1017
Ascierto et al., <i>Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies</i> , 37(5) Sem. Oncol. 508 (2010)	1018
Brahmer et al., <i>Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates</i> , 28(19) J. Clin. Oncol. 3167 (2010)	1019
National Institutes of Health, <i>A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors</i> , NCT01375842 clinicaltrials.gov (June 16, 2011)	1020
National Institutes of Health, <i>Multiple Ascending Dose (MDX1105-01) (Anti-PDL1)</i> , NCT00729664 clinicaltrials.gov (First posted August 7, 2008)	1021
Hwu, <i>Targeted therapy for metastatic melanoma: From bench to bedside</i> , Healio.com (June 25, 2010)	1022

Mu et al., <i>High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation</i> , 28 Med. Oncol. 682 (2010)	1023
File History for U.S. Patent No. 10,323,092 B2 (“the ’092 patent file history”)	1024
Topalian et al., <i>Cancer Immunotherapy Comes of Age</i> , 29(36) J. Clin. Oncol. 4828 (2011)	1025
Topalian et al., <i>Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity</i> , 24 Curr. Opin. Immunol. 207 (2012)	1026
PCT Publication No. WO 2007/005874 A2 (“WO874”)	1027
Tuthill et al., <i>Rapid infusion of rituximab over 60 min</i> , 82 Eur. J. Haematol. 322 (2009)	1028
M. Sznol, et al. Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies, Journal of Clinical Oncology 2010 28:15 suppl, 2506-2506	1029
U.S. Publication No. US 2010/0055102 A1	1030
U.S. Food & Drug Admin., <i>Erbix® (cetuximab), Highlights of Prescribing Information</i> (First approved 2004)	1031
U.S. Food & Drug Admin., <i>Vectibix® (panitumumab), Highlights of Prescribing Information</i> (First approved 2006)	1032
U.S. Food & Drug Admin., <i>Tysabri® (natalizumab), Highlights of Prescribing Information</i> (First approved 2004)	1033
Protocol for: Brahmer et al., Safety and activity of anti-PD-L1 antibody in patients with advanced cancer, N Engl J Med 2012;366:2455-65 (2012)	1038
Lee et al., <i>A one-hour infusion of infliximab during maintenance therapy is safe and well tolerated: a prospective cohort study</i> , 34 Aliment Pharmacol. Ther. 181 (2011)	1040
U.S. Patent No. 10,308,714 (“the ’714 patent”)	1049
U.S. Patent No. 10,266,594 (“the ’594 patent”)	1050
Jemal et al., <i>Cancer Statistics, 2009</i> , 59 CA Cancer J. Clin. 225 (2009) (“Jemal 2009”)	1051
Konishi et al., <i>B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression</i> , 10 Clin. Cancer Res. 5094 (2004) (“Konishi 2004”)	1052
U.S. Publication No. US 2009/0055944 A1	1053

(“the ’944 publication”)	
U.S. Publication No. US 2011/0250201 A1 (“Smith”)	1054
U.S. Publication No. US 2011/0244546 A1 (“Hansen”)	1055
<i>What is Non-Small Cell Lung Cancer?</i> American Cancer Society (2016) (“ACS”)	1056
Auperin et al., <i>Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer</i> , 28(13) J. Clin. Oncol. 2181 (2010) (“Auperin 2010”)	1057
U.S. Publication No. US 2010/0203056 A1 (“Irving”)	1058
U.S. Patent No. 9,580,505 (“the ’505 patent”)	1059
U.S. Patent No. 9,580,507 (“the ’507 patent”)	1060
U.S. Food & Drug Admin., <i>BENLYSTA® (belimumab), Highlights of Prescribing Information</i> (First approved 2011)	1061
Jacobs et al., <i>Bladder Cancer in 2010 How Far Have We Come?</i> , 60 CA Cancer J. Clin. 244 (2010)	1062
von der Maase et al., <i>Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer</i> , 23(21) J. Clin. Oncol. 4602 (2005)	1063
Drayton and Catto, <i>Molecular mechanisms of cisplatin resistance in bladder cancer</i> , 12(2) Expert Rev. Anticancer Ther. 271 (2012)	1064
Inman et al. <i>PD-L1 (B7-H1) Expression by Urothelial Carcinoma of the Bladder and BCG-Induced Granulomata</i> , 109(8) Cancer 1499 (2007)	1065
Nakanishi et al., <i>Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers</i> , 56 Cancer Immunol. Immunother. 1173 (2007)	1066
Galsky et al., <i>Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy</i> , 29(17) J. Clin. Oncol. 2432 (2011)	1067
Lenz, <i>Management and Preparedness for Infusion and Hypersensitivity Reactions</i> , 12 The Oncologist 601 (2007)	1068
Brahmer et al., <i>Safety and activity of anti-PD-L1 antibody in patients with advanced cancer</i> , N Engl J Med 2012;366:2455-65 (2012)	1069
Any other materials cited or referenced in my declaration	N/A